Next-Generation Cancer Immunotherapy
VitaNova Therapeutics is building a platform to discover and develop cancer-specific immunotherapies designed to transform the treatment of cancer.
Who We Are
Our approach focuses on identifying highly selective tumor antigens that enable the development of next-generation therapies including cellular immunotherapies, antibody-based medicines, and targeted immune engagers.
The company is being developed in collaboration with scientists and clinicians at the Fred Hutchinson Cancer Center, one of the world’s leading institutions in cancer research and cellular immunotherapy.
A Platform for Cancer-Specific Therapeutics
VitaNova’s platform is designed to unlock a new class of precision immunotherapies.
The company’s discovery approach enables multiple therapeutic modalities across a growing pipeline of oncology programs.
Cell-Surface Targets
These targets enable powerful immunotherapy approaches including:
CAR-T cell therapies
Antibody-Drug Conjugates (ADC)
T-cell engagers (BiTE)
NK-cell engager therapies
Intracellular Targets
Many of the most important cancer drivers exist inside tumor cells.
VitaNova identifies intracellular oncogenic proteins presented on peptide-HLA complexes, enabling the development of:
TCR-mimic antibodies
TCR-engineered cell therapies
Next-generation cellular immunotherapies
This dramatically expands the universe of druggable cancer targets.
Pipeline
VitaNova is advancing a growing pipeline of cancer-specific therapeutic programs across hematologic and solid tumors.
Initial development programs focus on:
Infant Acute Myeloid Leukemia (AML)
Osteosarcoma
High-risk pediatric malignancies
Additional programs are being developed across broader oncology indications.
Built on World-Leading Cancer Research
VitaNova Therapeutics is being developed in collaboration with scientists and clinicians at the Fred Hutchinson Cancer Center, a global leader in cancer biology and cellular immunotherapy.
This collaboration provides access to one of the world’s most advanced ecosystems for cancer discovery and clinical translation.
[ VitaNova Therapeutics Platform ]
[ Cancer-Specific Target Discovery ]
[ Cell Surface Targets ] [ Intracellular Targets ]
CAR-T | ADC | Engagers Peptide-HLA | TCR Mimics | TCR Therapies
[ Cancer Indications ]
AML | Osteosarcoma | Solid Tumors
Let’s Stay in Touch
For questions, collaborations, or scientific inquiries, please get in touch.